This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good morning, everyone. My name is Shelby, and I will be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceutical's second quarter 2023 financial results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star and one on your telephone keypad. As a reminder, this conference call is being recorded today, August 8, 2023. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead. Thank you, Shelby.
spk02: Welcome to Eagle Pharmaceuticals' second quarter 2023 earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tariff, Chief Financial Officer Brian Cahill, and Vice President of Medical Affairs, Dr. Michael Greenberg. This morning, EGLE issued a press release detailing its financial results for the three-month ended June 30th, 2023. This press release and a webcast of this call can be accessed through the investor section of the EGLE website at EGLE.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagle Pharmaceuticals management as of today and involve risks and uncertainties including those noted in this morning's press release and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's press release. The archived webcast will be available for 30 days on our website at eagleus.com. For the benefit of those who may be listening to the replay or archived webcast, this call is held and recorded on August 8, 2023. Since then, EGLE may have made announcements related to the topics discussed, so please refer to the company's most recent press releases and ICT file. We will be discussing non-GAAP financial measures during this call, in addition to financial information prepared in accordance with U.S. GAAP. These non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP. A description of these non-GAAP financial measures and reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are set forth in our earnings press release available on our website at EagleUS.com. And with that, I'll turn the call over to Eagle's President and CEO, Scott Taylor.
spk05: Scott Taylor Thank you, Lisa. Good morning, everyone, and thank you for joining our call today. We delivered a strong second quarter with impressive earnings and revenue. continuing the positive trajectory we've seen over the past 18 months. This morning, I will begin by discussing our financial and business highlights for the second quarter, as well as expectations for the remainder of the year. Brian will then provide a more detailed review of our second quarter financial performance and our updated guidance for 2023 before opening the call to Q&A. We entered 23 with a great deal of momentum from our outstanding performance in 22, and we built on that with strong Pemfexi numbers in the first half, market share retention for Vendeca and Belrapsso, and growing relaunch revenues for Barhempesis and Bifavos since our acquisition of these products from Acacia. We are obviously very pleased with the performance of our currently marketed drugs, both in oncology and in our hospital business. Once again, we posted strong earnings and revenue, and in fact, this is now the fourth consecutive quarter in which we have beaten consensus estimates. Reflecting on these and other positive factors that I'll discuss this morning, we recently raised our full-year guidance and in July resumed repurchases under our existing share repurchase program. Based on the higher guidance, we anticipate ending the year with over $100 million in net working capital. Let me provide some context here. We believe this expected working capital position is meaningful, considering how much money we anticipate having invested by the end of 23 across our products and pipeline. For 22 and 23, We anticipate to have invested $38 million in direct R&D to fund our product candidates, EA114 and CALA2. Additionally, we spent approximately $130 million, mostly cash, to acquire Acacia shares and debt, and $25 million to date for an equity position with an option to acquire Analar. This totals approximately $193 million, and we still find ourselves in this positive working capital position as we continue to generate positive cash flow. Over the past 12 months, we have also expanded our commercial teams, both in the hospital and oncology segments, and we now have a significant commercial infrastructure of about 80 people, which is included in the earnings and cash flow just discussed, and the revised upward guidance. We view our two sales forces as strategic assets to the company, which we will discuss further shortly. What we believe this means for the future is that Eagle could bring in additional products through R&D and or acquisition with minimal additional cost because of the commercial infrastructure we already have and therefore most of the revenue generated would fall to the bottom line. Now let's put everything in perspective for a moment. For fiscal year 22, we more than tripled non-GAAP earnings to just shy of $8 per share compared to 21, which was driven by approximately $230 million of gross profit in 22, excluding amortization expense. Adjusted non-GAAP EBITDA, grew more than 350 percent to $132 million for the fiscal year 22 compared to 21. For 23, we expect nearly the same gross profit as we saw in 22, excluding amortization expense. Although we increased our spending, our gross margin continues to be strong. In fact, our gross margin percent, excluding amortization, in the first half of this year was 83% compared to 74% in the first half of last year. And when you remove vasopressin, which was discontinued, our gross profit actually increased for the second quarter of 23 compared to the second quarter of 22. We expect this trend to continue going forward. The year-over-year decline in earnings per share is mostly due to these continued investments in R&D and our commercial infrastructure, which we believe positions us well for the future upside and is not a function of gross profit decline. We have been highly focused on our R&D initiatives and are working hard to ensure that each asset has the best chance of success. We're just a couple of weeks away from an important type C meeting with FDA for EA-114, our estrogen receptor antagonist project, which I'll discuss in more detail shortly. The investments we have made in our commercial infrastructure clearly paid off. We have more than tripled our market share of the non-340b pemetrexid market to approximately 21%, leaving Q2 up from 6% at the end of last year. It's important here to look at our balance sheet and receivables as well. The bulk of our receivables relate to Pemfexi at the end of the second quarter. For this product, we received the majority of our orders near the end of a quarter. Because contract pricing is mostly adjusted quarterly, large quantities of product are purchased near the end of the quarter, producing this result. This trend is likely to continue into the near future. Our quarter over quarter receivables balance is flat. indicating that we are in a normal cycle of payment and new revenue. Now, turning our attention to the Acacia acquisition, we are also very pleased with the relaunch efforts of Barhamsus and Bifavo within our hospital acute care segment. We characterize and treat both products as relaunches. As a reminder, our acquisition of Acacia was effective June 9th of 2022, about a year ago. Our fully trained and fully staffed sales force was first in action in Q1 of this year as we relaunched and Vicevo received its unique J-code in May. Now, please review the following slide. We now have two full quarters of sales data, and growth has been about 30 percent quarter over consecutive quarter since the relaunch. And we anticipate a similar growth rate to continue for the foreseeable future. In the second quarter of this year alone, we estimate that approximately 19,000 patients were dosed with Bar-Amsys or Bifavo, a very impressive number, reflecting the fact that the drugs are being embraced by our customers. In terms of penetration, two quarters in, approximately 275 healthcare facilities are purchasing product out of a targeted 4,000 entities in the United States. we see significant upside expansion potential here. I mentioned 19,000 patients a moment ago. Let me repeat this number. 19,000 patients were administered Baramsis or Bifavo in our second quarter of relaunch. Imagine what happens if half these entities are using our drugs, or if we increase our market share in each of these. You can see how the 19,000 could grow quickly. We'll see how the next several quarters go, but I hope you can feel the excitement we have about these two launches. Now let's discuss our oncology business. Gross profit, excluding amortization expense, in our oncology business was $43.8 million in the second quarter of 23, up from $38.7 million in the second quarter of last year, representing an impressive gross margin of 84% and 72%, respectively. Across the entire portfolio, our gross margin percentage, excluding amortization, has gone from 70% in the second quarter of 2022 up to 83% in the second quarter of this year. We anticipate that these trends will hold in the near to medium term. Hopefully, you can see that our gross profit and our gross profit margin continue to be very strong, as it has for the past year and a half. We are strategically investing in our business for future growth. Today, we have the largest commercial team that we've ever had, which is primed now to be able to bring more products into the company with minimal incremental expense, thus accelerating the bottom line as products come into the portfolio. We have been investing heavily in R&D as well as a way to expand our portfolio. We believe we are poised for future earnings growth based on the strength of our business and our R&D. The question remains then, how do we ensure growth going forward? The answer is simple. We need to add products through acquisition and or through our R&D pipeline. Fortunately, as we've discussed this morning, we believe we can bring in products with minimal additional commercialization expense. One potential opportunity is EA-114, our estrogen receptor antagonist program, which we have invested in over the past several years. We believe we have compelling data from our recent study of EA114, and we have a Type C meeting with FDA later this month. Once this meeting transpires, we will provide an update. Now turning to our hospital segment. We believe the hospital business is a great space with strong growth potential. We've already heard about the relaunch for Barhemsus and Bifavo, and CalO2 and NLR001 could also have significant potential. As people familiar with this space know, although hospital launches are slow, they are also generally rather sticky and profitable once well-established. Now let's discuss CalO2. As we recently announced, our Phase II study is underway, and our first patients have been randomized. The study is designed to assess the efficacy and safety of CalO2, which you may recall is a novel first-in-class antitoxin drug candidate. being developed to treat severe community-acquired bacterial pneumonia as an add-on to standard-of-care antibiotic therapy. CALO2 is a unique therapeutic agent that works differently from antibiotics, disarming the infectious pathogen's virulence factors to reduce damage and mitigate disease. It has been designed to neutralize a broad range of bacterial toxins to lessen the effect of virulence factors on disease progression and severity. We plan to enroll approximately 276 patients at more than 100 sites in over 20 countries worldwide. Our expectation is that we will have approximately 100 sites up and running before the year is over in readiness for the northern hemisphere's pneumonia season. In addition, we expect to have our interim results within the first half of 24. In June, FDA granted CalO2 QIDP designation under the GAIN Act. QIDP stands for Qualified Infectious Disease Product. CalO2 also received Fast Track designation. And let me briefly walk you through what this all means. QIDP designation entitles EGLE to an additional five years of marketing exclusivity upon approval. Eagle believes CalO2 qualifies as a new chemical entity, which would result in five years of marketing exclusivity upon approval or three years without MCE designation. In total, CalO2 may be eligible for a total of eight to ten years of marketing exclusivity upon approval. QIDP and fast-track designations underscore the significant unmet medical need in treating severe community-acquired bacterial pneumonia. Cal O2 also has patent protection through September of 2035 with filed patent applications that would extend to 2037 or later and may qualify for up to five additional years of patent term exclusivity as a new chemical entity up to 2040. Cal O2 has the potential to be a significant opportunity for us and a true paradigm shift in how healthcare providers combat this complex disease. We look forward to providing updates as the Cal O2 clinical program advances. Before I turn it over to Brian, let me reiterate once more how pleased I am that we were able to raise our guidance for the year. Very excited about the health of the business. And with that, I'll turn the call over to Brian Cahill to discuss our second quarter financials. Brian?
spk03: Thank you, Scott. And good morning. Let me share a few highlights from the financials we published in our press release this morning. In the second quarter of 2023, total revenue was $64.6 million compared to $74.1 million in Q2 of 2022. Net product sales during the second quarter of 2023 totaled $43 million compared to $49.2 million in Q2 of 2022. Confessing net product sales were $19.4 million in the second quarter of 2023 compared to $16.5 million in the second quarter of 2022. The increase is driven by our continued growth in market share that Scott discussed earlier. The RASA net product sales decreased to $6.8 million in the second quarter of 2023, compared to $8.1 million in Q2 of 2022. Second quarter Ryanadex net product sales were $10 million, compared to $8.8 million in the prior year quarter. Orders for Ryanadex are primarily driven by product expiry. with few customers requiring the interlink unless their stock is expiring. With this, our guidance considers Q3 to be lighter than the historical average. Second quarter of our hemp system by Fabo sales totaled $1.2 million. Q2 2023, royalty revenue was $21.7 million compared to $24.9 million in the prior year quarter. Royalty revenues include royalties earned on the sales of Bendecca in the U.S. and Triacosem in Japan. Gross margin was 74% in Q2 2023 compared to 68% in the prior year quarter. The increase was primarily driven, primarily, sorry, the result of increased Pemfexi sales, the expiration of Bendemusti royalty stream, and the buy-down of Pemfexi royalties. This is partially offset by the inclusion of amortization expense of intangible assets related to newly acquired products or hemp system by FAVO and our Confexi royalty buy-down, both of which we expect to continue going forward. Gross margin excluding amortization expense was 83% in the second quarter of 2023 compared to 70% in the prior year quarter. On the expense front, R&D expenses were $9.8 million for the second quarter of 2023 compared to $11.4 million in Q2 of 22. This decrease is largely attributable to the timing of our EA-114 program spend in 22, and it's partially offset by continuing CMC and clinical trial spend on our Cal O2 program and increased internal costs. excluding stock-based compensation and other non-cash and non-recurring items, second quarter 2023 non-GAAP R&D expense was $9.2 million. SG&A expenses in the second quarter of 2023 were $27.7 million, compared to $36.8 million in the second quarter of 22. This decrease was primarily driven by $17.6 million in costs related to the acquisition of Acacia, which will not recur. This is partially offset by incremental $2.9 million related to increased sales and marketing headcount, $2.4 million related to direct marketing support for Borhensis, Icevo, and Tempfexi, and $2.9 million in other general administrative expense partially related to these commercial efforts, excluding stock-based compensation and other non-cash and non-recurring items, second quarter 2023 non-GAAP SG&A expense was $23.8 million. Net income for the second quarter of 23 was $5.2 million, or 39 cents per basic and diluted share, compared to a net loss of $9.5 million, or 74 cents loss per basic and diluted share in the prior year quarter. Adjusted non-GAAP net income for the second quarter was $15.5 million, or $1.18 per basic and diluted share. and our adjusted non-GAAP EBITDA was $20.7 million for the second quarter. For a full reconciliation of non-GAAP measures to the most comparable GAAP measures, please see the table at the end of our press release. As of June 30th, 23, the company has $15.4 million in cash and cash equivalents, $115.1 million in net accounts receivable, and $71.3 million in outstanding debt. With that, I'll ask the operator to open the call for questions. Operator, please go ahead.
spk01: Thank you. At this time, if you would like to ask a question, please press the star and 1 on your telephone keypad. You may remove yourself from the queue at any time by pressing star 2. Once again, that is star and 1 to ask a question. We will pause for a moment to allow questions to queue. And we'll take our first question from Tim Lugo with Williams Player. Your line is open.
spk04: Thanks for taking my questions. And I've got a few for Brian. You detailed some expectations around Q3. I think you mentioned some seasonality in the quarter. Can you kind of expand on that? And, you know, we've also seen gross margins expanding. Can you also discuss some of the drivers there?
spk03: Sure, Tim. Good morning. Uh, thank you. So first on the, on the seasonality question, as you picked up, uh, I'm highlighting Rihanna decks, right? So Rihanna decks has a, uh, approximately 36 month shelf life. Uh, the cycle in which we sell the product in, uh, and the expert cycle really dictates most of when those sales will occur. Second quarter was, uh, an ebb, and third quarters expect to be a slight flow, right? So it'll be a little bit lower. But that cycle kind of continues on a wave depending on when those locks are expiring. And I tried to highlight, Tim, also some of the drivers around the margin differentials that we're experiencing in our business. And I'm trying to highlight for you you know, X amortization of what our real profitability looks like. And, you know, you'll recall, I hope, that we have a few factors going into our gross margin. We were previously weighted down with royalties that we used to pay on our at-bend and must-be franchise. Those have expired at the end of last year. So it actually increases our profitability in that area of our business. And for Confexi, we made the decision to buy down the majority of our royalty to another partner at the end of the last year. And with that, we have better profitability, gross margin, gross profit. And that was a great decision as you look back on that, what we did as far as looking at our forecast to buy down that royalty. It was really favorable for us, I think.
spk04: Okay, thanks for that detail. And I guess lastly, Barham's system is by favor. We see the growth. However, they're obviously relatively still smaller compared to the total franchise. What are kind of the expectations for that franchise over a one-year and maybe even two-year period? Is it going to be kind of continued steady growth, or will there be anything else swinging that?
spk05: Yeah, thanks, Tim. Scott, so look, we're just really very excited about it. I mean, as far as we're concerned, we've only been, you know, fully marketing these drugs for two quarters, and you can see the 30% growth. Our expectation is that this growth rate that we see is going to continue into the foreseeable future. You know, it's just going to keep growing. We're getting great feedback from our customers about Great acceptance. If you think that there's 275 hospitals buying now or, you know, facilities that could buy out of 4,000, and we have our most seasoned and the highest number of people in our sales force, most number of territories, you can see what happens. And I don't know how you feel about it, but the fact that 19,000 different patients used our drug in Q2 alone is very exciting. Our customers are obviously embracing it. They're reusing it or you wouldn't be able to get to this 19,000 number. And we expect that it's just going to keep growing. And then, you know, if you just multiply it out where this is going to go, you know, and not that too far of a distant future, it's going to be a very meaningful part of our business. And I think we're going to look back and be very pleased with the acquisition and combine that if we get good news on Calibre 2. We'll see what happens with Anilard, but in a few years, couple of years, we can be one of the leading hospital businesses in the marketplace. And we still think it's a great place to be. So we're more than excited right now about how it's going.
spk04: Understood. Thank you for that. And you're actively buying back shares, but obviously in the public markets, share prices have been weak year to date, and you're not the only one, obviously. Can you just maybe discuss a bit about where you think that disconnected?
spk05: Tim, that's a very good question. You know, from our perspective, we've really had a remarkable year and a half, right? And we'll wind up with a strong 23. And the fact that we rebased the business and we grew to $8 a share and this increase of 350% last year, and hopefully the takeaway is today, when you go through our script and our release, is that gross profit year over year is about the same, right? Our margins are growing in key segments of our business. We're bringing in quite a bit of profit. We've decided to spend some of that profit selectively and opportunistically into the future of the company. We're in a position to bring more products. And so, for instance, when EA114, if we're fortunate enough to bring that to the market, we don't need you know, much more additional expense to add that product into the company. We're waiting for data on Cal O2. We're waiting to come back from this FDA meeting. You know, I don't know where the disconnect is per se from a stock standpoint, but from a company standpoint, it's just been a great two years, and we're very excited about the future. And the future looks great, either through R&D. We'll see how the R&D works out. You know, we're very hopeful that our balance sheet and our cash position, you know, just puts in a great position to bring another product or two into the company. And so, you know, we think the future looks incredibly bright, great two years, and hopefully people figure it out and, you know, the stock will take care of itself because the earnings certainly have, and the R&D looks like it is, and these things have a tendency to work through.
spk04: Understood. Thank you for that.
spk05: Thank you, Tim.
spk01: And once again, if you would like to ask a question, please press star and 1 on your telephone keypad. Again, that is star and 1 to ask a question. We will pause for another moment to allow questions to queue. And it appears that we have no further questions at this time. I will now turn the program back over to Scott Tara for any additional or closing remarks.
spk05: Thank you again, everyone, for joining the call. I'm extremely proud of our performance this quarter. And as you've heard this morning, we have the foundation in place for another strong year in 23. Looking ahead, we intend to build our sales to leverage our commercial infrastructure and working capital position to add complementary products, either through R&D or acquisition, to advance the pipeline. And as always, we appreciate your ongoing support, and thank you for being on the call. Stay well. We appreciate it.
spk01: And that concludes today's teleconference. Thank you for your participation.
Disclaimer